Full Description
This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
Contents
Preface.- Angiogenesis assays: an appraisal of current techniques.- Survey of pro-angiogenesis strategies.- Angiogenesis modulation by arachidonic acid - derived lipids: positive and negative regulators of angiogenesis.- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects.- Actions of steroids and peptide hormones on angiogenesis.- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.- Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment.- Impact of nanotechnology on therapeutic angiogenesis.- Survey of anti-angiogenesis strategies.- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis.- Integrin antagonists and angiogenesis.- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology.- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration.- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit.- Biomarkers of response and resistance to anti-angiogenic treatment.- Speculations on new directions in which angiogenesis may proceed. Index.
